Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices

Abstract Objective COPD patients have challenges for effective use of inhalers due to advanced age, fixed airflow obstruction and comorbid medical conditions. Published clinical trials investigate drug efficacy but rarely consider the inhaler device. This trial investigates device efficacy, comparin...

Full description

Bibliographic Details
Main Authors: Haider Mannan, Soo Wei Foo, Belinda Cochrane
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Research Notes
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13104-019-4123-5
id doaj-95323fbf6347468380af5682382043df
record_format Article
spelling doaj-95323fbf6347468380af5682382043df2020-11-25T02:26:13ZengBMCBMC Research Notes1756-05002019-02-011211610.1186/s13104-019-4123-5Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devicesHaider Mannan0Soo Wei Foo1Belinda Cochrane2Translational Health Research Institute, Western Sydney UniversitySchool of Medicine, Western Sydney UniversitySchool of Medicine, Western Sydney UniversityAbstract Objective COPD patients have challenges for effective use of inhalers due to advanced age, fixed airflow obstruction and comorbid medical conditions. Published clinical trials investigate drug efficacy but rarely consider the inhaler device. This trial investigates device efficacy, comparing clinical outcomes for the same medication via two different devices. Our intention was to communicate the results and to critically appraise the study protocol to inform planning of future device comparison research. Subjects with spirometry confirming at least moderate COPD were randomly assigned to inhaler sequence; starting with Accuhaler or metered dose inhaler and spacer (MDI/s). After baseline testing, subjects were assigned to fluticasone propionate/salmeterol xinafoate (SFC) 500/50 mcg twice daily via the first device for 6 weeks’ duration, then changed to the alternate device for the following 6 weeks. Subjects were reassessed in terms of health-related quality of life (HRQL), exercise endurance and lung function after each exposure period. Results The recruitment target was not achieved due to unanticipated developments within the pharmaceutical industry, potentially compromising the study’s power. Study outcomes did not differ significantly according to the allocated inhaler device even after adjusting for baseline lung function or inhaler technique. Recommendations for future device comparison protocols are offered. Trial registration Australia and New Zealand Clinical Trials Registry, Current Controlled Trials ACTRN12618000075280, date of registration: 18.01.2018. Retrospectively registeredhttp://link.springer.com/article/10.1186/s13104-019-4123-5Cross overInhalation devicesPulmonary diseaseChronic obstructiveQuality of lifeAssessor-blind method
collection DOAJ
language English
format Article
sources DOAJ
author Haider Mannan
Soo Wei Foo
Belinda Cochrane
spellingShingle Haider Mannan
Soo Wei Foo
Belinda Cochrane
Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices
BMC Research Notes
Cross over
Inhalation devices
Pulmonary disease
Chronic obstructive
Quality of life
Assessor-blind method
author_facet Haider Mannan
Soo Wei Foo
Belinda Cochrane
author_sort Haider Mannan
title Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices
title_short Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices
title_full Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices
title_fullStr Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices
title_full_unstemmed Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices
title_sort does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (copd)? a comparative trial of two devices
publisher BMC
series BMC Research Notes
issn 1756-0500
publishDate 2019-02-01
description Abstract Objective COPD patients have challenges for effective use of inhalers due to advanced age, fixed airflow obstruction and comorbid medical conditions. Published clinical trials investigate drug efficacy but rarely consider the inhaler device. This trial investigates device efficacy, comparing clinical outcomes for the same medication via two different devices. Our intention was to communicate the results and to critically appraise the study protocol to inform planning of future device comparison research. Subjects with spirometry confirming at least moderate COPD were randomly assigned to inhaler sequence; starting with Accuhaler or metered dose inhaler and spacer (MDI/s). After baseline testing, subjects were assigned to fluticasone propionate/salmeterol xinafoate (SFC) 500/50 mcg twice daily via the first device for 6 weeks’ duration, then changed to the alternate device for the following 6 weeks. Subjects were reassessed in terms of health-related quality of life (HRQL), exercise endurance and lung function after each exposure period. Results The recruitment target was not achieved due to unanticipated developments within the pharmaceutical industry, potentially compromising the study’s power. Study outcomes did not differ significantly according to the allocated inhaler device even after adjusting for baseline lung function or inhaler technique. Recommendations for future device comparison protocols are offered. Trial registration Australia and New Zealand Clinical Trials Registry, Current Controlled Trials ACTRN12618000075280, date of registration: 18.01.2018. Retrospectively registered
topic Cross over
Inhalation devices
Pulmonary disease
Chronic obstructive
Quality of life
Assessor-blind method
url http://link.springer.com/article/10.1186/s13104-019-4123-5
work_keys_str_mv AT haidermannan doesdevicematterforinhaledtherapiesinadvancedchronicobstructivepulmonarydiseasecopdacomparativetrialoftwodevices
AT sooweifoo doesdevicematterforinhaledtherapiesinadvancedchronicobstructivepulmonarydiseasecopdacomparativetrialoftwodevices
AT belindacochrane doesdevicematterforinhaledtherapiesinadvancedchronicobstructivepulmonarydiseasecopdacomparativetrialoftwodevices
_version_ 1724848500757233664